WITHOFS, Nadia ; Centre Hospitalier Universitaire de Liège - CHU > Département de Physique Médicale > Service médical de médecine nucléaire et imagerie onco
Beguin, Yves ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie
COUSIN, François ; Centre Hospitalier Universitaire de Liège - CHU > Département de Physique Médicale > Service médical de médecine nucléaire et imagerie onco
Tancredi, Tino ; Division of Nuclear Medicine and Oncological Imaging, Medical Physics Department, CHU of Liège, Liège, Belgium
SIMONI, Paolo ; Centre Hospitalier Universitaire de Liège - CHU > Département de Physique Médicale > Département de Physique Médicale
Alvarez-Miezentseva, Victoria; Division of Diagnostic Imaging, Medical Physics Department, CHU of Liège, Liège, Belgium
DE PRIJCK, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
HAFRAOUI, Kaoutar ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
Cavo M, Terpos E, Nanni C, et al. Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206-e217.
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
Caers J, Garderet L, Kortum KM, et al. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018;103(11):1772-1784.
Mangiacavalli S, Pezzatti S, Rossini F, et al. Implemented myeloma management with whole-body low-dose CT scan: a real life experience. Leuk Lymphoma. 2016:1-7;57(7):1539-1545.
Hillengass J, Moulopoulos LA, Delorme S, et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J. 2017;7(8):e599.
Moreau P, Attal M, Karlin L, et al. Prospective evaluation of MRI and PET-CT at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial. Blood. 2015;126(23):395.
Pawlyn C, Fowkes L, Otero S, et al. Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia. 2016;30(6):1446-1448.
Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [ 18 F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017:JCO2017722975;35(25):2911-2918.
Lee SY, Kim HJ, Shin YR, Park HJ, Lee YG, Oh SJ. Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis. Eur Radiol. 2016;27(6):2333-2347.
Mai EK, Hielscher T, Kloth JK, et al. Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. Eur Radiol. 2016;26(11):3939-3948.
Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068-2076.
Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989-5995.
Spinnato P, Bazzocchi A, Brioli A, et al. Contrast enhanced MRI and 18 F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. Eur J Radiol. 2012;81(12):4013-4018.
Zamagni E, Nanni C, Mancuso K, et al. PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21(19):4384-4390.
McDonald JE, Kessler MM, Gardner MW, et al. Assessment of total lesion glycolysis by 18 F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2016;23(8):1981-1987.
Regelink JC, Raijmakers PG, Bravenboer N, et al. 18 F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma. EJNMMI Res. 2016;6(1):46.
Xu F, Liu F, Pastakia B. Different lesions revealed by 18F-FDG PET/CT and 18F-NaF PET/CT in patients with multiple myeloma. Clin Nucl Med. 2014;39(9):e407-e409.
Nishiyama Y, Tateishi U, Shizukuishi K, et al. Role of 18 F-fluoride PET/CT in the assessment of multiple myeloma: initial experience. Ann Nucl Med. 2013;27(1):78-83.
Sachpekidis C, Goldschmidt H, Hose D, et al. PET/CT studies of multiple myeloma using 18 F-FDG and 18 F-NaF: comparison of distribution patterns and tracers' pharmacokinetics. Eur J Nucl Med Mol Imaging. 2014;41(7):1343-1353.
Ak I, Onner H, Akay OM. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT. Ann Hematol. 2015;94(9):1567-1575.
Sachpekidis C, Hillengass J, Goldschmidt H, et al. Treatment response evaluation with 18 F-FDG PET/CT and 18 F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Eur J Nucl Med Mol Imaging. 2017;44(1):50-62.
Minamimoto R, Loening A, Jamali M, et al. Prospective comparison of 99m Tc-MDP scintigraphy, combined 18 F-NaF and 18 F-FDG PET/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med. 2015;56(12):1862-1868.
Mattsson S, Johansson L, Leide SS, et al. Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances. Ann ICRP. 2015;44(2 Suppl):7-321.
Waheed S, Mitchell A, Usmani S, et al. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica. 2012;98(1):71-78.
Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50-55.
Lapa C, Garcia-Velloso MJ, Luckerath K, et al. 11 C-methionine-PET in multiple myeloma: a combined study from two different institutions. Theranostics. 2017;7(11):2956-2964.
Hur J, Yoon CS, Ryu YH, Yun MJ, Suh JS. Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography. J Comput Assist Tomogr. 2007;31(3):342-347.
Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG. Pieters-van den Bos IC, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol. 2013;162(1):50-61.
Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657-664.
Dutoit JC, Vanderkerken MA, Anthonissen J, Dochy F, Verstraete KL. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. Eur Radiol. 2014;24(11):2754-2765.